Metraipolis › archive › dc_2df483594291

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial — Europe PMC PMID:41404513

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41404513
DOI
10.3389/fendo.2025.1716247
License (as archived)
solo-consultazione
Archived
2026-11-08T01:34:54.382Z
SHA-256 of the archived text
18d7b21c385fd07e4c5ee7738a7c1eda3be53cf89ec18ee969868d536550f1a8
Stable URL of this page
https://metraipolis.com/documento/dc_2df483594291

How to cite

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial — Europe PMC PMID:41404513 — Europe PMC (en), https://europepmc.org/article/MED/41404513 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2df483594291 (Metraipolis archive dc_2df483594291, sha256 18d7b21c385fd07e4c5ee7738a7c1eda3be53cf89ec18ee969868d536550f1a8)
BibTeX
@misc{dc2df483594291,
  title = {Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial — Europe PMC PMID:41404513},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41404513},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2df483594291; sha256 18d7b21c385fd07e4c5ee7738a7c1eda3be53cf89ec18ee969868d536550f1a8},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41404513. Agents can read the archived copy with the MCP tool read_document.